Nature communications · 2025
Pre-existing and early cellular immune factors correlate with functionally complete protection against primary controlled human SARS-CoV-2 infection.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wagstaffe Helen R, Thwaites Ryan S, Sidhu Jasmin K, Lindeboom Rik G H, Kretschmer Lorenz, Worlock Kaylee B, Dratva Lisa M, Huang Ao, Ascough Stephanie, Papargyris Loukas, McKendry Richard, Collins Ashley M, Xu Jiayun, Lemm Nana-Marie, Killingley Ben, Kalinova Mariya, Mann Alex, Catchpole Andrew, Swadling Leo, Tsang John S, Maini Mala K, Noursadeghi Mahdad, Nikolić Marko Z, Teichmann Sarah A, Openshaw Peter J M, Chiu Christopher
Аннотация
Identifying host factors that mediate protection against newly-emergent viruses is needed for improved pandemic preparedness. Here, we analysed pre- and early post-exposure immune factors associated with resisting SARS-CoV-2 infection after human challenge in seronegative individuals, using multiplex protein, cytometric and RNA sequencing approaches in the nasopharynx and circulation. Pre-existing cross-reactive antibodies correlate poorly with clinical outcome. Instead, protection is associated with heightened nasopharyngeal CCL13 levels locally produced by conventional dendritic cells and monocytes, along with cross-reactive T cells and less differentiated NK cells. Conditional independence network analysis implicates nasal CCL13 as the central node connected to pre-existing non-structural protein-specific T cells by CD1c+ DCs. In those who became infected, baseline cross-reactive T cell and less differentiated NK cell frequencies also correlate with shorter infection duration. Thus, pre-existing mucosal chemokine levels may promote rapid innate and innate-like responses that effectively block infection. ClinicalTrials.gov identifier NCT04865237.